MR-Base

MR-Base performs Mendelian randomization analyses by providing access to a curated GWAS summary-statistic repository and analytical methods to investigate causal relationships between genetic variants and phenotypes.


Key Features:

  • Database Integration: Integrates a curated GWAS summary-statistic database containing 11 billion single nucleotide polymorphism-trait associations from 1677 GWAS without filtering by statistical significance.
  • Analytical Capabilities: Supports 2-sample Mendelian randomization to estimate causal effects between phenotypes using genetic instruments and automates two-sample MR analyses.
  • Sensitivity Analyses: Implements sensitivity analyses to assess horizontal pleiotropy and other potential violations of Mendelian randomization assumptions.

Scientific Applications:

  • Phenome-wide causal scans: Enables phenome-wide scans to explore millions of potential causal associations across diverse phenotypes using GWAS summary statistics.
  • Causal discovery and hypothesis testing: Supports novel causal analyses and hypothesis-driven investigations of exposure–outcome relationships.
  • Replication and validation: Facilitates replication of causal findings across independent GWAS datasets.
  • Risk factor and drug-target appraisal: Aids identification of risk factors and appraisal of potential drug targets using causal evidence from MR.

Methodology:

Implements 2-sample Mendelian randomization using genetic variants as instrumental variables and GWAS summary statistics, with sensitivity analyses for horizontal pleiotropy and without requiring individual-level data.

Topics

Details

License:
MIT
Tool Type:
command-line tool, web application
Programming Languages:
R
Added:
11/14/2019
Last Updated:
11/24/2024

Operations

Publications

Walker VM, Davies NM, Hemani G, Zheng J, Haycock PC, Gaunt TR, Davey Smith G, Martin RM. Using the MR-Base platform to investigate risk factors and drug targets for thousands of phenotypes. Wellcome Open Research. 2019;4:113. doi:10.12688/wellcomeopenres.15334.1. PMID:31448343. PMCID:PMC6694718.

PMID: 31448343
PMCID: PMC6694718
Funding: - Medical Research Council: MC_UU_00011/1, MC_UU_00011/4, MC_UU_00011/6 - Cancer Research UK: C18281/A19169 - Wellcome Trust: 208806

Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7. doi:10.7554/elife.34408. PMID:29846171. PMCID:PMC5976434.

PMID: 29846171
PMCID: PMC5976434
Funding: - Wellcome: 208806/Z/17/Z - Cancer Research UK: C18281/A19169, Population Research Postdoctoral Fellowship, C52724/A20138 - Medical Research Council: Methodology Research Fellowship, MR/N501906/1 - National Institute for Health Research: NIHR Bristol BRC - National Health and Medical Research Council: APP1125200, APP1137714 - Roy Castle Lung Cancer Foundation: 2013/18/Relton

Links